Edoardo Crimini

Dr. Edoardo Crimini

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
CCChiara Corti
Chiara Corti
ECEdoardo Crimini
Edoardo Crimini
PTPaolo Tarantino
Paolo Tarantino
GPGabriella Pravettoni
Gabriella Pravettoni
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont
GCGiuseppe Curigliano
Giuseppe Curigliano

1 July 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
ECEdoardo Crimini
Edoardo Crimini
MRMatteo Repetto
Matteo Repetto
PAPhilippe Aftimos
Philippe Aftimos
ABAndrea Botticelli
Andrea Botticelli
PMPaolo Marchetti
Paolo Marchetti
GCGiuseppe Curigliano
Giuseppe Curigliano

29 September 2025 in Nature Medicine
Verified
Journal Article
Open access
PMPaolo Marchetti
Paolo Marchetti
GCGiuseppe Curigliano
Giuseppe Curigliano
MBMauro Biffoni
Mauro Biffoni
SLSara Lonardi
Sara Lonardi
SSSimone Scagnoli
Simone Scagnoli
FMFrancesca Mannozzi
Francesca Mannozzi
Despite recent advancements demonstrating the potential of tumor-agnostic biomarkers to guide effective therapies, randomized evidence supporting the clinical superiority of precision oncology approaches compared to standard therapies remains limited. The ROME trial was a multicenter, randomized, open-label phase 2 study comparing tailored treatment (TT) to standard of care (SoC) in patients with advanced solid tumors progressing after one or two lines of therapy. Comprehensive genomic profiling on tissue and blood was performed to identify actionable alterations. Overall response rate (ORR) was the primary endpoint, and progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), time to next treatment (TTNT) and safety were the secondary endpoints. Between November 2020 and August 2023, 1,794 patients were screened, 897 were evaluated by the molecular tumor board (MTB) and 400 were randomized to TT or SoC. TT achieved a significantly higher ORR (17.5% versus 10%; P = 0.0294) and improved median PFS (3.5 months versus 2.8 months; hazard ratio = 0.66 (0.53–0.82), P = 0.0002). TT also showed superior 12-month PFS rates (22.0% versus 8.3%). Median OS was similar, with a 52% crossover rate. Grade 3/4 adverse events were also similar (40% TT versus 52% SoC). These results highlight the potential of TT to improve outcomes for patients with diverse actionable genomic alterations. These results also provide relevant evidence supporting a tumor-agnostic precision oncology strategy and highlight the potential of TTs, guided by genomic profiling and MTB recommendations, to significantly improve outcomes for patients with diverse actionable genomic alterations. ClinicalTrials.gov identifier: NCT04591431.

1 June 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
DTD. Trapani
D. Trapani
SGS. Gandini
S. Gandini
CCChiara Corti
Chiara Corti
ECEdoardo Crimini
Edoardo Crimini
FBF. Bellerba
F. Bellerba
GCGiuseppe Curigliano
Giuseppe Curigliano

1 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CBCarmen Belli
Carmen Belli
GAGabriele Antonarelli
Gabriele Antonarelli
MRMatteo Repetto
Matteo Repetto
LBLuca Boscolo Bielo
Luca Boscolo Bielo
ECEdoardo Crimini
Edoardo Crimini
GCGiuseppe Curigliano
Giuseppe Curigliano
Cancers are composed of transformed cells, characterized by aberrant growth and invasiveness, in close relationship with non-transformed healthy cells and stromal tissue. The latter two comprise the so-called tumor microenvironment (TME), which plays a key role in tumorigenesis, cancer progression, metastatic seeding, and therapy resistance. In these regards, cancer-TME interactions are complex and dynamic, with malignant cells actively imposing an immune-suppressive and tumor-promoting state on surrounding, non-transformed, cells. Immune cells (both lymphoid and myeloid) can be recruited from the circulation and/or bone marrow by means of chemotactic signals, and their functionality is hijacked upon arrival at tumor sites. Molecular characterization of tumor-TME interactions led to the introduction of novel anti-cancer therapies targeting specific components of the TME, such as immune checkpoint blockers (ICB) (i.e., anti-programmed death 1, anti-PD1; anti-Cytotoxic T-Lymphocyte Antigen 4, anti-CTLA4). However, ICB resistance often develops and, despite the introduction of newer technologies able to study the TME at the single-cell level, a detailed understanding of all tumor-TME connections is still largely lacking. In this work, we highlight the main cellular and extracellular components of the TME, discuss their dynamics and functionality, and provide an outlook on the most relevant clinical data obtained with novel TME-targeting agents, with a focus on T lymphocytes, macrophages, and cancer-associated fibroblasts.

31 January 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
MRMatteo Repetto
Matteo Repetto
ECEdoardo Crimini
Edoardo Crimini
LBLuca Boscolo Bielo
Luca Boscolo Bielo
EGElena Guerini-Rocco
Elena Guerini-Rocco
LALiliana Ascione
Liliana Ascione
GCGiuseppe Curigliano
Giuseppe Curigliano